Rhinovirus Infection Therapeutics - Pipeline Analysis 2018, Clinical Trials and Results, Patents, Designations, Collaborations, and Other Developments

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 History

4.3 Signs and Symptoms

4.4 Complications

4.5 Diagnosis

4.6 Treatment

4.7 Key Drivers

4.7.1 Increasing Collaboration Between Companies

4.7.2 Positive Clinical Results

4.7.3 Increasing Prevalence of Rhinovirus Infections

4.8 Key Barriers

4.8.1 Increasing Healthcare Cost

4.8.2 Several Types of Rhinovirus

4.9 Rhinovirus Infection Therapeutics Pipeline Analysis

4.9.1 Pipeline Analysis by Phase

4.9.2 Pipeline Analysis by Molecule Type

4.9.3 Pipeline Analysis by Route of Administration

4.9.4 Pipeline Analysis by Company

Chapter 5. Rhinovirus Infection Therapeutics Pipeline Analysis by Phase (2018)

5.1 Phase III

5.1.1 Nitazoxanide

5.1.1.1 Clinical trials

5.2 Phase II

5.2.1 Vapendavir

5.2.1.1 Clinical trials

5.2.1.2 Clinical trial results

5.2.2 XXXX

5.2.2.1 Clinical trials

5.2.2.2 Clinical trial results

5.2.3 XXXX

5.2.3.1 Clinical trials

5.2.4 XXXX

5.2.4.1 Clinical trials

5.2.4.2 Clinical trial results

5.2.5 Comparative Analysis of Phase II Drugs

5.3 Pre-Clinical

5.3.1 TVB-3567

5.3.1.1 Pre-Clinical study

5.3.2 XXXX

5.3.2.1 Strategic development

5.3.2.2 Technology

5.3.3 XXXX

5.3.3.1 Strategic development

5.3.4 XXXX

5.3.4.1 Technology

5.4 Discovery

5.4.1 MIMESIS program

5.4.1.1 Grant

5.4.1.2 Technology

Chapter 6. Clinical Trials Review

6.1 Clinical Trials by Region

6.2 Clinical Trials by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking

7.2 SWOT Analysis

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 3-V Biosciences Inc.

8.1.1 Business Overview

8.1.2 Product and Service Offerings

8.2 XXXX

8.2.1 Business Overview

8.2.2 Product and Service Offerings

8.3 ENYO Pharma SA

8.3.1 Business Overview

8.3.2 Product and Service Offerings

8.4 XXXX

8.4.1 Business Overview

8.4.2 Product and Service Offerings

8.5 Vaxart Inc.

8.5.1 Business Overview

8.5.2 Product and Service Offerings

8.6 Romark L.C.

8.6.1 Business Overview

8.6.2 Product and Service Offerings

8.7 XXXX

8.7.1 Business Overview

8.7.2 Product and Service Offerings

8.8 XXXX

8.8.1 Business Overview

8.8.2 Product and Service Offerings

8.9 XXXX

8.9.1 Business Overview

8.9.2 Product and Service Offerings

8.10 XXXX

8.10.1 Business Overview

8.10.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

List of Tables

TABLE 1 PIPELINE ANALYSIS OF RHINOVIRUS INFECTION THERAPEUTICS, BY COMPANY (2018)

TABLE 2 DESCRIPTION OF NITAZOXANIDE

TABLE 3 CLINICAL TRIALS OF NITAZOXANIDE

TABLE 4 DESCRIPTION OF VAPENDAVIR

TABLE 5 CLINICAL TRIALS OF VAPENDAVIR

TABLE 6 VAPENDAVIR PHASE II TRIAL RESULTS

TABLE 7 DESCRIPTION OF XXXX

TABLE 8 CLINICAL TRIALS OF XXXX

TABLE 9 PLECONARIL PHASE II TRIAL RESULTS

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 CLINICAL TRIALS OF XXXX

TABLE 12 DESCRIPTION OF XXXX

TABLE 13 CLINICAL TRIALS OF XXXX

TABLE 14 PREP-001 PHASE II TRIAL RESULTS

TABLE 15 COMPARATIVE ANALYSIS OF PHASE II DRUGS

TABLE 16 DESCRIPTION OF TVB-3567

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 DESCRIPTION OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 DESCRIPTION OF MIMESIS PROGRAM

TABLE 21 3-V BIOSCIENCES INC. – AT A GLANCE

TABLE 22 XXXX – AT A GLANCE

TABLE 23 ENYO PHARMA SA – AT A GLANCE

TABLE 24 XXXX – AT A GLANCE

TABLE 25 VAXART INC. – AT A GLANCE

TABLE 26 ROMARK L.C. – AT A GLANCE

TABLE 27 XXXX – AT A GLANCE

TABLE 28 XXXX – AT A GLANCE

TABLE 29 XXXX - AT A GLANCE

TABLE 30 XXXX – AT A GLANCE

List of Figures

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH BY REGION

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 4 RHINOVIRUS INFECTION THERAPEUTICS UNDER DEVELOPMENT (2018)

FIG 5 RHINOVIRUS INFECTION THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2018)

FIG 6 RHINOVIRUS INFECTION THERAPEUTICS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2018)

FIG 7 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 8 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 9 KEY PLAYERS BENCHMARKING

FIG 10 SWOT ANALYSIS